Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph not_applicable

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

N/ANon-phased studies

2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(1)

Detailed Status

Completed1

Not yet recruiting1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

completed133%

not_yet_recruiting133%

recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingnot_applicable

Middle Meningeal Artery Embolization for Chronic Subdural Hematomas (STORMM)

NCT06163547

not_yet_recruiting

Chronic Subdural Hematoma Embolization With Detachable Coils

NCT07291427

completednot_applicable

Embolization of the Middle Meningeal Artery for the Prevention of Chronic Subdural Hematoma Recurrence in High Risk Patients (EMPROTECT)

NCT04372147

Clinical Trials (3)

Showing 3 of 3 trials

NCT06163547Not Applicable

Middle Meningeal Artery Embolization for Chronic Subdural Hematomas (STORMM)

Recruiting

NCT07291427

Chronic Subdural Hematoma Embolization With Detachable Coils

Not Yet Recruiting

NCT04372147Not Applicable

Embolization of the Middle Meningeal Artery for the Prevention of Chronic Subdural Hematoma Recurrence in High Risk Patients (EMPROTECT)

Completed

All 3 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 3